1 Thread .Cochrane crisis about the HPV vaccines’ review: some Marc Arbyn’s conflicts of interests. @PGtzsche1
2 As we can see in the pub Med index of publications ncbi.nlm.nih.gov/pubmed?term=Ar…, Marc Arbyn, who is presented as an epidemiologist , coordinator of the Belgian center of cancer epidemiology
3 Has spent most of his time, specially since 2004, advocating for the for the widespread use of HPV tests on behalf of the European cervical cancer association based in Lyon onlinelibrary.wiley.com/doi/epdf/10.10…
4 We don’t know what this ECCA exactly is except that it has no employees and is registered as a non for profit society specialised in biothech research and development societe.com/societe/europe…
5 In 2007 Marc Arbyn published his first review about HPV vaccines effectiveness thelancet.com/journals/lance…
6 The scope of this review was to find an explanation to the low effectiveness of HPV quadrivalent vaccine 
7 And above all to tell that this lower effectiveness than expected was not due to serotype replacement
8 For this study Marc Arbyn received travel grants from Sanofi Pasteur MSD and GSK
9 Marc Arbyn has also published many studies like this one cebp.aacrjournals.org/content/22/3/4… in the” Cancer epidemiology biomarkers and prevention” review that is an AACR publication.
10 The AACR is widely funded by pharmaceutical companies including Merck aacrfoundation.org/Pages/our-dono…
11 And, last but not least, in 2017 Marc Arbyn published an article titled “Overcoming barriers in HPV vaccination and screening programs” sciencedirect.com/science/articl…
12 This article was authored by the” The Human Papillomavirus Prevention and Control Board” that was supported by unrestricted grants from the vaccine industry, that is GSK and Merck.
